by guest www.bloodjournal.org From MS# BLOOD-2015-672071 FIRST EDITION 1/11/2016 8:55 AM 2 KEY POINTS
INTRODUCTION
Graft-versus-host disease (GVHD) continues to compromise the overall success of allogeneic hematopoietic cell transplantation (HCT). Although rates and severity of acute GVHD have decreased with improvements in donor selection criteria, pharmacologic prophylaxes, and supportive care, rates of chronic GVHD have remained remarkably stable at 35-50% for many years. 1 The median duration of systemic immunosuppressive treatment for chronic GVHD is approximately 2.5 years after bone marrow transplantation (BMT) and 3.5 years after mobilized blood cell transplantation. Since chronic GVHD contributes to long-term morbidity and mortality after allo-HCT, strategies that prevent this complication without compromising beneficial graftversus-tumor (GVT) effects are urgently needed.
Recent studies have convincingly shown that high-dose cyclophosphamide (Cy) given early after HCT does not compromise engraftment and can decrease the risk of chronic GVHD. In studies of HLA-haploidentical BMT with reduced-intensity conditioning, Cy was given at 50 mg/kg on days 3 and 4 or only on day 3 followed by tacrolimus and mycophenolate mofetil (MMF). [2] [3] [4] The cumulative incidence frequencies of grades II-IV GVHD and grades III-IV GVHD were 34% and 6%; the cumulative incidence frequencies of chronic GVHD were 25% after a single dose of Cy and only 5% after 2 doses of Cy. 3 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From In a prospective phase II study, high-dose Cy was given as single-agent prophylaxis on days 3 and 4 after HLA-matched related or unrelated BMT with busulfan/cyclophosphamide conditioning. 5 The cumulative incidence frequencies of grades II-IV GVHD, grades III-IV GVHD and chronic GVHD were 43%, 10% and 10%. In a follow-up study, high-dose Cy was given on days 3 and 4 after HLA-matched related or unrelated BMT with busulfan/fludarabine conditioning. The cumulative incidence frequencies of grades II-IV GVHD, grades III-IV GVHD and chronic GVHD were 51%, 15% and 14%. Taken together, these results show that the cumulative incidence of chronic GVHD is consistently less than 15% when high-dose Cy is given as the sole GVHD-prophylaxis after HLA-matched related or unrelated BMT. 6 Compared to bone marrow, the relative ease of procurement combined with faster neutrophil and platelet reconstitution after transplant have made growth factor-mobilized blood a popular graft source for allogeneic HCT. When a calcineurin inhibitor and an antimetabolite are used for immunosuppression after allogeneic HCT, however, the advantage of earlier hematopoietic reconstitution is offset by a higher risk and longer duration of chronic GVHD. [7] [8] [9] The present study was therefore designed to address this problem by determining whether the low incidence of chronic GVHD associated with the use of high-dose Cy after BMT could be replicated in patients who received mobilized blood cell grafts. Cyclosporine (CSP) was added in an effort to reduce the risk of grades 3-4 acute GVHD that had been reported to range from 10%-15% in earlier studies of HLA-matched BMT where high-dose Cy was the sole means of postgrafting immunosuppression. 5, 6 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
METHODS

Study design
The primary endpoint of the study was the cumulative incidence of chronic GVHD (defined by NIH criteria 10 ) requiring systemic immunosuppressive treatment compared with the historic rate of 35%. 11 Major secondary endpoints included grades II-IV and III-IV acute GVHD, need for systemic treatment of acute GVHD, persistent or recurrent malignancy after HCT, disease-free and overall survival.
Patients
Eligibility criteria included the following: patients 65 years of age or younger with a high-risk hematologic malignancy as defined (see Supplemental Data); peripheral blood stem cell donor who was either a genotypically HLA-identical sibling, a phenotypically HLA-matched first-degree relative, or an unrelated donor who was matched with the patient at HLA-A, B, C and DRB1 by molecular methods. Initially, unrelated donors mismatched with the patient at a single class I antigen were eligible for the study. After the first transplant from an HLA-A-antigen mismatched unrelated donor resulted in poor graft function requiring second transplant, the protocol was amended to exclude HLA-mismatched donors. Exclusion criteria included the following: Patients who had received prior autologous or allogeneic HCT, an ECOG performance status >2, uncontrolled infections, pregnancy or organ dysfunction as defined (see Supplemental Data).
The institutional review board of the Fred Hutchinson Cancer Research Center approved this study and all patients provided written informed consent before enrollment, in accordance with the Declaration of Helsinki. The characteristics of patients, donors and transplant regimens are summarized in Table 1 .
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Preparative and immunosuppressive regimens
Participants received one of two preparative regimens (i) FLU/ T BU, which consisted of fludarabine 40 mg/m2/day IV followed by targeted IV busulfan on days -5 until -2 or (ii) fractionated TBI at a cumulative dose of 12 Gy or higher (12 Gy, n=13; 13.2 Gy, n=5) on days -5 until -2 (Figure 1) . In general, patients with myeloid malignancies received the FLU/ T BU regimen while those with lymphoid malignancies received TBI. The initial IV busulfan dose was 130 mg/m 2 /day for patients 18 years of age or older; 0.8 mg/kg IV every 6 hours for patients from 10-17 years of age; 1 mg/kg IV every 6 hours for patients less than 10 years of age) (n=25). All subsequent busulfan doses were adjusted in real time to targeted steady-state concentrations (Css) of 800-900 ng/mL. 12 G-CSF-mobilized peripheral blood mononuclear cells were collected by leukapheresis on days -1 and 0 and the products from both days were infused on day 0. A second collection on day 0 was not required if the collection on day -1 yielded at least 5x10 6 CD34 cells/kg recipient weight. Cy was given at 50 mg/kg/day IV on days 3 and 4 after graft infusion. Mesna was administered on days 3 and 4 for urothelial protection. An intravenous loading dose of CSP was given on day 5 followed by subsequent twice daily dosing adjusted to maintain whole blood trough concentrations at 120-360 ng/mL. In the absence of GVHD, CSP doses were tapered from day 56 through day 126.
Cyclophosphamide Pharmacokinetics
Cy pharmacokinetics were evaluated with each cyclophosphamide dose in 31 patients. For logistical reasons, 12 patients did not contribute samples to this analysis. Samples were collected at 1 (end of infusion), 2, 4, 8, 16, and 24 hours from the start of the infusion. The 24hr samples were collected before the start of the subsequent dose. Samples were placed at 4°C within 5 minutes of collection and were processed within 18 hours. Concentrations of Cy, carboxyethylphosphoramide mustard (CEPM), deschloroethylcyclophosphamide (DCCy), and For personal use only. on October 28, 2017. by guest www.bloodjournal.org From ketocyclophosphamide (KetoCy) were measured as previously reported, 13 except using liquid chromatography with tandem mass spectrometry (LC/MS/MS). The dynamic range of the assays of Cy and its metabolites were as follows: Cy, 0.96 to 192µM; CEPM 0.043 to 17µM; DCCy 0.063 to 25µM; KetoCy 0.022 to 9.1µM. All assays had an inter-day precision within 10%. The plasma exposure is the area under the plasma concentration -time curve from time 0 to 48 h (AUC0-48h). The AUCs were estimated according to noncompartmental modeling with Phoenix (Pharsight, St. Louis, MO).
Treatment of GVHD
First-line treatment of acute GVHD was prednisone 0.5 to 2 mg/kg/day, according to severity of symptoms. 14 In patients with gastrointestinal GVHD, systemic prednisone treatment was combined with oral beclomethasone dipropionate emulsion (BDP; 4 mg/day) and enteric-coated budesonide (6 mg/day). Treatment with CSP was continued as tolerated. Prednisone doses were tapered as GVHD symptoms resolved. Decisions regarding the timing and choice of secondary therapy were made at the discretion of the attending physician.
Statistical analysis
Primary endpoint. The primary endpoint of this study was the cumulative incidence of chronic GVHD at 1 year after transplantation. Chronic GVHD was defined by NIH criteria as requiring systemic immunosuppressive treatment. The cumulative incidence of this endpoint in patients prepared with myeloablative regimens after HCT from HLA-matched related or unrelated donors has been approximately 35%. 11 A reduction in the cumulative incidence of chronic GVHD from ~35% to ~15% at 1 year was considered a reasonable goal after HCT with growth factor-mobilized blood cells. A sample size of 42 patients provided 90% power to observe such a difference with one-side 5% type-1 error. The analysis plan specified that For personal use only. on October 28, 2017. by guest www.bloodjournal.org From survival rates at one year would be evaluated to determine whether a low cumulative incidence of chronic GVHD could be explained by an excessive number of early deaths.
Secondary endpoints. Grades II-IV and II-IV acute GVHD, non-relapse mortality and recurrent or progressive malignancy were assessed with the use of cumulative incidence estimates. Disease-free and overall survival rates were evaluated as Kaplan-Meier estimates.
Donor engraftment was assessed with descriptive statistics summarizing the median proportions of donor myeloid cells and T cells in the blood at day 28. In addition, the proportions of patients with full and mixed chimerism were summarized. Hematologic recovery was assessed through descriptive statistics summarizing the median days to neutrophil and platelet recovery. Graft failure was assessed through descriptive statistics summarizing the incidence of primary graft failure and secondary graft failure.
RESULTS
Patient, donor and allograft characteristics
Patient, donor and allograft characteristics are summarized in Table 1 
Engraftment
The median times to neutrophil engraftment to 0.5 × 10 3 /μL and platelet engraftment to 20 × 10 3 /μL were 19 (range, 16 to 37) days and 14 (range, 10 to 47) days, respectively, for patients with primary engraftment. One patient had primary engraftment failure. This patient had familial MDS (GATA2 mutation) and had received a graft from an HLA A-antigen mismatched unrelated donor. Peripheral blood chimerism for both CD3 and CD33 consistently showed >95% donor signal. The patient received a second transplant using 2 umbilical cord blood units after reduced-intensity conditioning. Engraftment did not occur, and the patient died with multi-organ failure on day 41 after the second transplant. Even though causality between the transplant regimen and engraftment failure in this patient was never established, the protocol was subsequently modified to exclude patients with HLA-antigen mismatched donors.
GVHD
The cumulative incidence frequencies of grades 2-4 and 3-4 acute GVHD at day 100 were 77% and 0%, respectively (Figure 2A) . Among patients with acute GVHD, 19% developed grade IIb symptoms characterized by rash involving more than 50% of the body surface. No patient with acute GVHD developed stage 2 gastrointestinal manifestations (stool volume ≥ 1.0L/day). Acute GVHD was treated with glucocorticoids in all patients (initial methylprednisolone-equivalent dose, 0.5-2.0 mg/kg/day). At 1 year after transplant, only 3 patients continued immunosuppressive treatment for management of acute GVHD without meeting criteria for NIHdefined chronic GVHD. There was no identifiable association between patient age and risk of acute GVHD (not shown).
The cumulative incidence of NIH-defined chronic GVHD requiring systemic immunosuppressive treatment at 1 year, which was the primary endpoint of the study, was 16% (95% CI, 5% to 28%) ( Figure 2B ). All cases of chronic GVHD occurred within the first year after transplant. We also analyzed the cumulative incidence of extensive chronic GVHD defined by traditional criteria, 15 although this outcome was not a formal endpoint of this study. At 1 year, the cumulative incidence of extensive chronic GVHD was 30% (95% CI, 17% to 44%). The following variables were evaluated as possible predictors of chronic GVHD but were not statistically significant: unrelated donor vs. related donor (HR 1.11; 95% CI 0.2-5.7; p=0.90) ( Figure 2C) ; 
Relapse, NRM, progression-free survival and survival
At 2 years, the cumulative incidences of recurrent malignancy and NRM were 17% (95% CI, 5% to 29%) and 14% (95% CI, 4% to 25%), respectively (Figure 3) . The Kaplan-Meier overall survival estimate at 2 years was 70% (95% CI, 55% to 85%), and the estimate of progressionfree survival at 2 years was 69 (95% CI, 54% to 83%). Of the 42 patients (98%) followed for at For personal use only. on October 28, 2017. by guest www.bloodjournal.org From least one year, 21 (50%) were relapse-free and alive without systemic immunosuppression at 1
year after HCT.
Exploratory analysis showed that patients prepared with high-dose TBI had a significantly higher 2-year survival likelihood than those prepared with FLU/ T BU (83% vs. 59%) (Supplemental Figure 1) . The interpretation of these results is confounded by the preponderance of high-risk myeloid malignancies and the older age of patients treated with FLU/ T BU (median age, 52 vs. 23.5 years, p=0.05). Patients with leukemia or MDS who had minimal residual disease at the time of transplant (n=14) had significantly worse progression-free survival (38% versus 90%, p=0.002) and overall survival (45% versus 85%, p=0.009) compared to those who did not have minimal residual disease (n=22) (Figure 4) . μ M×h for ketoCY. According to preparative regimen, the AUC 0-48h of Cy was higher in patients treated with TBI without phenytoin (n=9) than in those treated with FLU/ T BU (n=22) (p<0.0001) with phenytoin, while the AUCs of ketoCY were lower (p=0.03) (Figure 5) . The AUCs of CEPM and DCCY did not show statistically significant differences according to the preparative regimen (p=0.05 and 0.14; For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
Cyclophosphamide pharmacokinetics according to preparative regimen
DISCUSSION
In this study, we explored the safety and efficacy of Cy-based GVHD-prophylaxis after HLAmatched related or unrelated mobilized blood cell transplantation with either FLU/ T BU or TBI (≥12 Gy) myeloablative conditioning. The 16% cumulative incidence of NIH-defined chronic GVHD at 1 year was substantially lower than that observed in studies of HCT with either marrow or mobilized blood cells from HLA-matched related or unrelated donors. The incidence of grade 2 acute GVHD was high, but unlike previous studies with the use of high-dose Cy after HLAmatched BMT, we observed no cases of grades 3 or 4 acute GVHD, and no cases of grade 2 acute GVHD with high-volume diarrhea (stool volume ≥ 1.0L/day). The results showed low risks of NRM and recurrent malignancy, translating to an overall projected survival rate of 70% at 2 years. Of the patients followed for at least one year, 50% were relapse-free and alive without systemic immunosuppression at 1 year after HCT.
The use of mobilized blood cells has demonstrated benefits of easier procurement, more rapid engraftment and superior control of high-risk malignancies. These benefits have made growth factor-mobilized blood the most common source of stem cells used at many transplant centers.
The main disadvantage of using mobilized blood cell grafts, however, is the significant increase in risk and duration of chronic GVHD. [7] [8] [9] We observed a low incidence of chronic GVHD in the current study, even though the proportion of the patients with HLA-matched related donors (30%) was lower than in the study used to set the benchmark (44%). 11 Therefore, the results suggest that the risk of chronic GVHD associated with mobilized blood cell grafts can be substantially reduced by using high-dose Cy and CSP after HCT. By applying NIH criteria for comparing the incidence of chronic GVHD, the 16% incidence in our study (primary endpoint) is comparable to the 18% incidence when high-dose Cy was given after HLA-haploidentical transplantation of mobilized blood cells 16 
and the 10-14% incidence when high-dose Cy was
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From given after HLA matched related or unrelated BMT. 5, 6 Although not a formal endpoint in this study, a statistically significant reduction in the risk of chronic GVHD to 30% (95% CI, 17% to 44%) was also observed after applying the "traditional" chronic GVHD grading system 15 to our study population. In a contemporaneous control cohort given mobilized blood cell grafts from HLA-matched related or unrelated donors after myeloablative conditioning (n=168), the cumulative incidence of chronic GVHD requiring systemic treatment at 1 year after HCT was 54% (unpublished).
In previous studies testing high-dose Cy alone for immunosuppressive prophylaxis after HLAmatched related or unrelated BMT, the cumulative incidence rates of severe (grades 3-4) acute GVHD were between 10% and 15. 5, 6 For this reason, our study regimen included immunosuppression with CSP initiated on post-transplant day 5, the day after the second dose of Cy. Although 77% of patients developed grade 2 acute GVHD in our study, we did not observe severe (grade 3-4) manifestations, and no patient developed stage 2 gastrointestinal involvement (stool volume ≥ 1 L/day). In addition, previous studies have shown that after HCT with myeloablative conditioning, grade 2 acute GVHD had no effect on survival but was associated with a decreased risk of relapse. 17 The generally increased incidence of grade 2 acute GVHD reported at our center has been attributed to high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement. 18 Thus, our findings suggest that the addition of a calcineurin-inhibitor to high-dose Cy after HLA-matched growth factor-mobilized blood transplantation can significantly reduce the risk of severe acute GVHD.
Nevertheless, optimizing the GVHD prophylactic regimen to reduce the risk of even mild-tomoderate acute GVHD would be desirable to further reduce the morbidity associated with this complication.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Approximately half of the patients had minimal residual disease or active disease at the time of HCT. Although absence of minimal residual disease was associated with superior progressionfree survival and overall survival (Figure 4) , our results suggest that effective prevention of chronic GVHD was not offset by an increased risk of recurrent malignancy. We speculate that the high incidence of mild grade 2 acute GVHD and low incidence of chronic GVHD reflect residual immunological activity of donor cells against recipient cells that is sufficient to mediate graft-versus-leukemia effects after myeloablative conditioning. If these findings can be confirmed in future studies, the practice of allo-HCT with mobilized blood cells could change with the adoption of high-dose Cy combined with a calcineurin inhibitor as the mainstay of posttransplant immunosuppressive prophylaxis.
In addition to FLU/ T BU, high-dose TBI (≥12 Gy) was safely combined with high-dose posttransplant Cy in this study. The use of TBI allowed treatment of patients with diseases for which the FLU/ T BU regimen would not be optimal, such as ALL, high-risk AML and lymphoma.
Although 89% of patients given high-dose TBI/Cy received grafts from HLA-matched unrelated donors, the toxicity observed with this approach was exceptionally low (2-year NRM, <10%) resulting in a 2-year overall survival estimate of 90%. Given the promising results with high-dose TBI (≥12 Gy) and high-dose post-transplant Cy in this subset of study patients, larger confirmatory studies with this regimen are warranted.
Cy is a prodrug with complex metabolism. Dosing Cy by body weight led to considerable interpatient variability in the AUCs of Cy and its metabolites, consistent with our previous data. 19 Formation of 4-hydroxycyclophosphamide (4HCy) is critical because this intermediate is transported intracellularly and subsequently metabolized to acrolein and phosphoramide mustard, the latter functioning as a bifunctional alkylator of DNA and the ultimate cytotoxic metabolite of Cy. HCy is detoxified to 4-ketocyclophosphamide (ketoCy) by cytochrome P-450
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From and carboxyethylphosphoramide mustard (CEPM) by aldehyde dehydrogenase 1 (ALDH1). 20, 21 Notably, acrolein is the only Cy metabolite that inhibits ALDH1 activity in vivo. 20 Cy plasma exposure was lower in patients given FLU/ T BU with phenytoin compared to those given TBIbased conditioning without phenytoin (Figure 5) , but the heterogeneity of the patient population and the low event rates of chronic GVHD and relapse made it difficult to determine whether plasma exposure of Cy and its metabolites was associated with clinical outcomes. The lower exposure in patients given FLU/ T BU is consistent with our prior data with T BU/Cy 22 and presumably reflects the inductive effects of phenytoin, which was used to prevent busulfan- In conclusion, high-dose Cy in combination with CSP after myeloablative HLA-matched mobilized blood cell transplantation resulted in low rates of both chronic GVHD and severe acute GVHD. In conjunction with high-dose pre-transplant conditioning, the immunosuppressive regimen was safe, and effective GVHD-protection did not compromise control of underlying malignancy. If these findings are confirmed in future studies, HLA-matched mobilized blood cell transplantation may gain even greater acceptance and further replace marrow as a source of stem cells for most indications.
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